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Abstrak 
Metode yang berbasis antagonistik langsung antara bakteri laut dan Staphylococcus 
aureus resistan metisilin (Methicillin-resistant Staphylococcus aureus, MRSA) 
berhasil digunakan untuk skrining bakteri laut penghasil senyawa anti-MRSA. 
Metode ini menggunakan medium agar lapis ganda untuk mendukung 
pertumbuhan bakteri laut dan MRSA. Beberapa bakteri laut penghasil senyawa 
anti-MRSA berhasil diisolasi dengan metode ini. Suatu bakteri laut, strain O-BC30 
merupakan bakteri yang paling kuat menghambat pertumbuhan MRSA. Isolat-
isolat bakteri yang didapat menunjukkan aktivitas yang stabil terhadap MRSA dan 
aktivitas ini juga konsisten dengan aktivitas ekstrak yang diperoleh dari sel bakteri 
yang dikultur pada medium agar. Metode ini sangat berguna dan efisien untuk 
skrining bukan hanya bakteri penghasil senyawa anti-MRSA tetapi juga bakteri 
penghasil antibiotik. 
Kata kunci : Antagonistik, Senyawa Anti-MRSA, Methicillin-resistant Staphylococcus 
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Introduction 
The National Nosocomial Infections 
Surveillance reports an increase trend of 
MRSA by 40% in 1999 comparing to 1994-
1998 and occupies 52.3% of S. aureus 
nosocomial infection (NNIS, 2000). MRSA are 
well known gram-positive bacteria that are able 
to produce -lactamase (Williams, 1999). This 
enzyme encoded by the gene BlaZ, hydrolyses 
-lactam antibiotics and greatly diminishes or 
even eliminates their biological activity. 
MRSA also produces penicillin-binding 
protein, PBP 2a that attributes to the resistance 
of this bacterium to methicillin and others 
penicillinase-resistant penicillin. Penicillin 
binding proteins (PBPs) as the bacterial target 
of -lactam antibiotics, are enzyme 
transpeptidase that maintain the structural 
integrity of the bacterial polysaccharides cell 
wall. MRSA is able to produce new 
transpeptidase, PBP 2a (Williams, 1999; 
Archer and Bosilevac, 2001; Zhang et al., 
2001). 
MRSA is one of the leading causative 
agents of deadly nosocomial infection. The 
mortality for bacteremia caused by MRSA is 2-
fold higher than that caused by Methicillin-
sensitive Staphylococcus aureus (MSSA) 
(Selvey et al., 2000). MRSA also causes longer 
hospital stay and 3-fold higher hospital cost 
(Abramson and Sexton, 1999). Vancomycin is 
the only commercially available antibiotic to 
control MRSA infection. However, recently, 
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the susceptibility of MRSA to vancomycin has 
become reduced and rather vancomycin-
intermediumte (VISA) and -resistant S. aureus 
(VRSA) are found in several countries. The 
above evidences have made the currently 
available antibiotics and chemotherapeutics 
ineffective, necessitating to search alternative 
antibiotics and chemotherapeutics. Therefore, 
this study were conducted to develop screening 
method and to find potent anti-MRSA 
substance-producing marine bacteria as new 
resources of antibiotics, especially new anti-
MRSA substances. 
Materials and Methods 
Bacterial strains 
A clinical isolate (7B29) and a reference 
strain (ATCC 33291) of MRSA were used in 
this study. These strains were stocked in TSB 
containing 20% of glyserol at -80C. 
Seawater samples 
Seawater samples were collected from 
Ogasawara Island (Tokyo prefecture), Iki 
Island and Shimabara (Nagasaki Prefecture), 
and Kashiwa Jima Island (Saga Prefecture), 
Japan in spring and summer 1998 – 1999. The 
samples were kept in a cool box and 
transported to laboratory.  
Sample preparation, antagonistic assay 
and isolation of bacterial strains 
Seawater samples were serially diluted in 
sterile ASW if necessary, and plated onto 
ZoBell agar medium [polypepton (Katayama), 
5 gr/l; yeast extract (Nihon Seiyaku), 1 gr/l; 
glucose (Katayama), 2 gr/l; KBr, 100 mg/l 
dissolved in 75% ASW] and incubated at 25oC 
for 18 – 24h until bacterial colony grown 
enough. The bacterial colony grew on the plate 
then were overlaid with MRSA-inoculated 
0.8% agar of Trypticase Soy Agar (TSA) 
medium (Difco Laboratories, Detroit MI, USA) 
at final concentration 1 x 106 cell/ml, and 
incubated at 25oC for 24 h. The antagonistic 
activity of colonies against MRSA was 
observed after 24 h incubation, and active 
colonies were isolated on ZoBell agar medium. 
This activity was used to guide the isolation of 
anti-MRSA substance producing marine 
bacteria. Further the anti-MRSA activity of 
bacterial isolates was confirmed on double 
layer plate as described above. After the agar 
medium have solidified, marine bacteria 
isolates were stab-inoculated onto the double 
layer agar by a straight needle.  
Production and isolation of anti-MRSA 
substance 
To produce anti-MRSA substance, the 
marine bacterial isolates were cultured on 
ZoBell agar medium plate (10  14 cm) at 
25C for 5 days. Bacterial cells were harvested 
by flooding MeOH onto the agar lawn and 
scrapping gently by a glass spreader. MeOH 
volume in each bacterial cell suspension then 
was adjusted to be 10 ml/g of wet weight cell, 
homogenized with a homoginizer (Polytron PT 
3000; Kinematica, Tokyo) at 10,000 rpm for 15 
min. Then MeOH extracts were obtained by 
centrifugation at 3,000 x g for 20 min. This 
extraction was carried out twice in the same 
volume of MeOH (10 ml MeOH/g cell). 
Homogenization was conducted by the same 
procedure as used in the first extraction. 
Finally, these MeOH extracts were filtered 
through 0.2 m of filter paper (Millipore, 
Tokyo, Japan). 
To explore anti-MRSA substance from 
intracellular rather than cell wall-bounded 
substance, cell pellets obtained from the second 
MeOH extraction was added with 10 ml 
MeOH/1 g cell, and sonicated (Branson 
Sonifier 250; Sonic Power Co., Dunbury CT, 
USA) for 15 min on ice bath. The sonicated 
cell suspensions were subsequently centrifuged 
at 5,000 g for 15 min, and supernatants were 
filtered through the same filter paper as 
described above. 
Evaluation of anti-MRSA activity of 
MeOH extracts 
Anti-MRSA activity of MeOH extracts 
from each bacterial strain were evaluated by 
paper disk diffusion method on double layer 
agar of Trypticase Soy Agar (TSA) medium 
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(Difco Laboratories, Detroit MI, USA) as 
described previously (Horikawa et al., 1999; 
Isnansetyo et al., 2001) after 10-fold 
concentrated. Sterile paper disks (ø 8 mm, 
Advantec) was impregnated with 50 l of each 
MeOH extract, and dried at 25C. Vancomycin 
at 2 g/disk was used as a positive control. 
Melted 0.8% agar of TSA medium 
incubated in water bath at 48C was inoculated 
with an overnight culture of MRSA (ATCC 
33591) to give an initial bacterial density of 106 
cells/ml, and overlaid onto 1.5% TSA medium 
plate. After the medium had solidified, dried 
MeOH extracts-impregnated paper disks were 
placed on the plates and incubated at 37C for 
24 h. The intensity of anti-MRSA activity was 
considered by measuring clear zone around the 
paper disks. Then the most active MeOH 
extracts were partitioned with CHCl3 after 
being added with the same volume of water. 
Determination of Minimum inhibitory 
concentrations (MICs) of the CHCl3 
extracts 
The minimum inhibitory concentrations 
(MICs) of the CHCl3 extracts from the most 
potent anti-MRSA substance-producing marine 
bacteria were determined by the standard 
microdilution method described by the 
National Committee for Clinical Laboratory 
Standards (1997), using cation-adjusted Muller 
Hinton Broth (CAMHB) medium (Difco 
Laboratories, Detroit, MI, USA) containing 20 
µg/ml Ca++ and 10 µg/ml Mg++. The final 
volume of CAMHB containing the CHCl3 
extracts was 100 l per well to give a starting 
inoculum density of MRSA at 5  105 cells/ml. 
Results and Discussion 
The screening purposes in this report are 
to discover potent anti-MRSA substance-
producing marine bacteria as new resources of 
antibiotics, and to develop the efficient 
detecting method by direct antagonistic assay. 
This assay significantly improves the 
efficiency of screening process because the 
anti-MRSA strains are easily detected to 
isolate. The anti-MRSA activity-guided 
isolation also drastically reduces the time-
consuming than the conventional isolation 
method. By this direct antagonistic assay, large 
amount of bacterial colonies could be screened 
for anti-MRSA activity. 
Marine bacteria originated from a total 
of 39 seawater samples were evaluated for anti-
MRSA activity by direct antagonistic assay. 
All colonies possessing potent anti-MRSA 
activity (Figure 1) were obtained from seawater 
samples collected in Ogasawara Island, Tokyo, 
but not from the other sampling points. The 
total colony tested for anti-MRSA activity was 
approximately 50,000 colonies. 
Ten isolates of anti-MRSA substance-
producing marine bacteria were successfully 
isolated by this new screening procedure. In the 
final step of the isolation, the isolates were 
evaluated for their anti-MRSA activities on 











Figure 1. Direct antagonistic method for detecting anti-MRSA substance-producing 
marine bacteria by overlying MRSA-suspended soft agar onto marine 
bacterial colonies. Arrow heads indicate the anti-MRSA activity by the 
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Figure 2 shows that ten of the isolates 
exhibited potent anti-MRSA activity indicating 
clear zones around the growth colonies of these 
marine bacteria. The antibacterial potency of 
each isolate might be predicted by the intensity 










  Figure 2. Anti-MRSA activities of marine bacterial isolates. 
1, strain O-BC30; 2, strain O-BCX1; 3, strain O-BC40(B); 4, strain O-
BCX3; 5, strain O-BC12; 6, strain O-WC12; 7, strain O-BC20; 8, strain 
O-GC20; 9, strain O-GC14; 10, strain O-TCX1; 11, strain O-GC13; 12, 
strain O-TC11; 13, strain O-GC16; C, negative control (Vibrio 
parahaemolyticus V-7). 
 
Table 1. Anti-MRSA activity of the MeOH extract from newly isolated anti-MRSA marine bacteria 
Strain MeOH extracts from cell pellets MeOH extracts from sonicated cells 
O-BC12 - - 
O-BC20 ++ - 
O-BC30 ++ - 
O-BCX3 ++ - 
O-BC40(B) ++ - 
O-GC13 - - 
O-GC14 - - 
O-GC16 - - 
O-TCX1 + - 
O-TC11 - - 
Note : (-) not inhibition (+) low inhibition (++) strong inhibition 
 
To confirm the above results and to 
produce anti-MRSA substance, each bacterial 
strain was cultured on ZoBell agar medium to 
determine the most potent anti-MRSA 
substance-producing marine bacteria among 
the ten marine bacterial isolates. The MeOH 
extracts from each bacterial cell were evaluated 
for the anti-MRSA activity, and the result is 
presented in Table 1. This second screening 
was able to determine four most potent isolates, 
strains O-BC20, O-BC30, O-BCX3, and O-
BC40 (B), and a bacterial isolate O-TCX1 also 
exhibited moderate anti-MRSA activity. 
However, such an activity was not detected 
even in 10-fold concentrated MeOH extracts of 
both bacterial cell pellets and sonicated cells 
from other five bacterial isolates. Undetectable 
anti-MRSA activity in these extracts might be 
due to low concentration of active substances 
at sub MIC even though these samples were 
10-fold concentrated. This hypothesis was 
proved by extraction of these MeOH extracts 
with CHCl3. The anti-MRSA activity of these 
five strains was barely detected at 500 µg/disk 
of the CHCl3 extracts. 
The third screening was conducted to 
determine the most potent anti-MRSA 
substance-producing marine bacterium among 
strains O-BC20, O-BC30, O-BCX3, and O-
BC40 (B). In this final screening, samples were 
prepared by CHCl3 extraction and the anti-
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dilution method to determine the MIC. Strain 
O-BC30 was the most potent anti-MRSA 
bacterium. MIC of its CHCl3 extract against 
MRSA was 6.25 µg/ml, 2-fold lower than the 
same extracts from the other three bacterial 
strains O-BC20, O-BCX3, and O-BC40 (B). 
This result indicated that strain O-BC30 is the 
most potent anti-MRSA substance producing 
marine bacterium found in this screening. 
Then strain O-BC30 was characterized 
and identified by morphological, biochemical, 
physiological and genetic methods. The results 
indicated that this bacterium is a new species in 
the genus Pseudoalteromonas. When anti-
MRSA substance produced by this strain was 
purified and their chemical structures were 
elucidated, phenolic anti-MRSA substances 
were found. Therefore, Pseudoalteromonas 
phenolica sp. nov. was proposed name for this 
novel bacterium (Isnansetyo and Kamei, 
2003a, 2003b). 
Thus, although massive efforts have been 
continued to discover chemically new 
structural antibiotics, more than 90% of all 
bioactive compounds from terrestrial 
microorganism are reported to be already 
known compounds (Fenical, 1993). This direct 
antagonistic method may be used widely to 
discover antibiotic-producing marine bacteria 
as a new resources for antibiotics. 
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